Disease activity as assessed by the magnetic resonance imaging in multiple sclerosis (MAGNIMS) score predicts long-term clinical disease activity (CDA)-free status and disability progression in patients treated with subcutaneous interferon beta-1a (scIFNβ-1a)

Authors
Category Primary study
JournalNeurology
Year 2018
This article has no abstract
Epistemonikos ID: 6659572db02ae31fb2dfcf48137e24c8494cd265
First added on: Feb 09, 2025